Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina
HI Henderson, DA Wohl, WA Fischer… - Journal of …, 2024 - academic.oup.com
Background In the USA, nirmatrelvir/ritonavir is authorized for the treatment of mild-to-
moderate COVID-19 in patients at least 12 years of age, at high risk for progression to …
moderate COVID-19 in patients at least 12 years of age, at high risk for progression to …
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study
K Hansen, SR Makkar, D Sahner, J Fessel, N Hotaling… - medRxiv, 2023 - medrxiv.org
Importance COVID-19 has placed a monumental burden on the health care system globally.
Although no longer a public health emergency, there is still a pressing need for effective …
Although no longer a public health emergency, there is still a pressing need for effective …
Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China …
X Han, C Li, X Yuan, J Cui, Z Han, J Meng… - Annals of …, 2024 - Taylor & Francis
Background The effectiveness of nirmatrelvir–ritonavir has mainly been shown in non-
hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19). The real …
hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19). The real …
Real-world effectiveness of nirmatrelvir/ritonavir on coronavirus disease 2019–associated hospitalization prevention: a population-based cohort study in the province …
JL Kaboré, B Laffont, M Diop, MR Tardif… - Clinical Infectious …, 2023 - academic.oup.com
Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
[HTML][HTML] Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during …
Background Effectiveness of oral antivirals in mild-to-moderate COVID-19 patients is
urgently needed. This retrospective cohort study aims to evaluate the clinical and virologic …
urgently needed. This retrospective cohort study aims to evaluate the clinical and virologic …
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO …
I Gentile, A Giaccone, MM Scirocco, F Di Brizzi… - medRxiv, 2024 - medrxiv.org
Introduction Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
CA Gentry, P Nguyen, SK Thind, G Kurdgelashvili… - Journal of infection, 2023 - Elsevier
Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …
States (US) through the Food and Drug Administration (FDA) emergency use authorization …